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the gut microbiome in dogs 
with congestive heart failure: 
a pilot study
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David J. connollyͷ
compromised gut health and dysbiosis in people with heart failure has received a great deal of 
attention over the last decade. Whether dogs with heart failure have a similar dysbiosis pattern to 
what is described in people is currently unknown. We hypothesised that dogs with congestive heart 
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failure. However, there was an increase in abundance of proteobacteria in the congestive heart failure 
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show additional trends in our data suggesting that dogs may have a similar pattern to that described 
in people. the results of this study provide useful preliminary information and raise the possibility that 
dogs represent a clinically relevant animal model of dysbiosis in people with heart failure.
!e gut microbiota is a consortium of microorganisms in the digestive  tract1. In addition to contributing to 
digestion, these organisms function as an endocrine organ through the production of bioactive metabolites and 
modulate the immune system through the translocation of immunomodulatory bacterial products across the 
intestinal  wall1. In people, alteration in the microbiota, also known as dysbiosis, is recognised in diseases includ-
ing chronic kidney disease, in"ammatory bowel disease, heart failure and obesity, suggesting involvement of the 
microbiota in their pathophysiology and  progression1–8. Similar changes in the microbiota have been identi#ed 
for some of these diseases in veterinary medicine, but not for heart failure to  date9–13.
!e contribution of the gut microbiota in the development and maintenance of heart failure known as the 
“gut-hypothesis” details impaired gut health in heart failure patients, resulting in dysbiosis and bacterial translo-
cation across the oedematous mucosal  layer14–16. !is results in immune-stimulation via endotoxins, contributing 
to a chronic in"ammatory state, malnutrition and cachexia. While this has been the focus for evaluation of novel 
therapies in people with advanced heart failure, no such research has been described in veterinary  medicine1,16,17. 
Congestive heart failure (CHF) is a common cardiac presentation in dogs, with typical signs comprising severe 
respiratory distress, due to pulmonary oedema or pleural e$usion or abdominal distension due to ascites. Medi-
cal management is successful in many cases, but dogs with CHF, particularly those with right sided congestive 
heart failure (RCHF), are o%en euthanised due to progressive inappetence and severe cachexia, even when their 
heart failure is adequately  managed18. Reduced appetite and cachexia are also recognized in dogs with le% sided 
congestive heart failure (LCHF), due to acquired mitral valve disease, and are independently associated with 
 outcome19,20. Evaluation of the gut microbiota in these dogs could enhance our understanding of gut health in 
heart failure and the subsequent deleterious pro-in"ammatory systemic sequelae, such as cardiac cachexia. If 
dogs show a similar dysbiosis pattern to people, they could potentially serve as a clinically relevant animal model 
for people with heart failure.
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Results
Study population.  A total of 50 dogs were enrolled, of which 15 were healthy (control) and 35 had CHF. 
Seventeen dogs in the CHF group were living with other dogs in the same household. Eight of these cohabiting 
dogs were included in the control group. !e CHF group comprised 16 LCHF, 15 RCHF, and 4 biventricular 
congestive heart failure (BiCHF) dogs. !e causes of CHF were myxomatous mitral valve degeneration (n = 19), 
dilated cardiomyopathy (n = 13), congenital heart disease a$ecting the tricuspid and pulmonic valves (n = 2), 
and pulmonary hypertension (n = 1). !ere was no di$erence in age, body weight or sex between the control and 
CHF groups. However, the CHF group had a lower body condition score (BCS) (p = 0.005), muscle condition 
score (MCS) (p < 0.001) and appetite (p < 0.001) than the control group. All healthy dogs and most CHF dogs 
(96.0%) were eating commercial dog food as their primary diet, however, more owners were supplementing their 
dogs with human foods in the CHF group (5/15 control dogs vs 23/35 CHF dogs, p = 0.061). !ese human foods 
consisted mainly of what the owner was eating on the day and were mostly protein based with no added salt 
(i.e. cooked chicken or white #sh). Two dogs with CHF were exclusively eating human foods (cooked lamb and 
pasta for one dog, cooked chicken and vegetables for the other). Further demographic data is listed in Table 1. 
Additional information on breed and diet for each CHF subgroup (LCHF, RCHF and BiCHF) is listed in Sup-
plementary Table S1 online.
Table 1.  Demographic characteristics of the control and congestive heart failure (CHF) groups. a One dog 
in the CHF group was missing a muscle condition score. !e results are displayed as median [25th, 75th 
percentiles] as they were non-normally distributed. Statistical signi#cance (p < 0.05) is marked bold.
Control (n = 15) CHF (n = 35) p value
Age (years) 8.0 [6.9–10.0] 10.2 [7.9–10.9] 0.141
Sex 0.462
Female (%) 7 (46.7%) 10 (28.6%)
Neutered: entire 7:0 10:0
Male (%) 8 (53.3%) 25 (71.4%)
Neutered: entire 5:3 15:10
Breeds (%) 0.106
Small breeds 4 (26.7%) 18 (51.4%)
Large breeds 11 (73.3%) 17 (48.6%)
Body weight (kg) 20.3 [12.1–33.0] 12.0 [7.3–42.5] 0.352
BCS (/9) 0.005
1/9 0 1 (2.9%)
2/9 0 4 (11.4%)
3/9 0 8 (22.9%)
4/9 3 (20.0%) 4 (40.0%)
5/9 6 (40.0%) 6 (17.1%)
6/9 6 (40.0%) 2 (5.7%)
Muscle conditiona < 0.001
Normal 15 (100%) 8 (22.8%)
Mild 0 11 (31.4%)
Moderate 0 9 (25.7%)
Severe 0 6 (17.1%)
Diet
Dog food 15 (100%) 33 (94.3%) 1.000
Human food 5 (33.3%) 23 (65.7%) 0.061
Appetite < 0.001
Normal 15 (100%) 13 (37.1%)
Reduced 0 22 (62.9%)
Duration of CHF (weeks) – 6.0 [3.0–28.0] –
Medication
Diuretic dose (mg/kg/day) – 4.4 [3.4–7.1] –
Furosemide 0 28 (80.0%) –
Torsemide 0 4 (11.4%) –
Pimobendan 0 33 (94.3%) –
Benazepril 0 25 (71.4%) –
Spironolactone 0 23 (65.7%) –
Fish oil 0 4 (11.4%) –
Diltiazem/digoxin 0 9 (25.7%) –
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Ǥ !ere were 28,374,445 reads generated by the Illumina sequencing of the 50 
samples submitted. !e assessment of alpha diversity is summarised in Table 2. !ere was no signi#cant di$er-
ence in the alpha diversity between the control versus CHF groups when assessed using operational taxonomic 
unit, Shannon diversity index or Faith’s phylogenetic diversity (Fig. 1). Beta diversity, analysed based on Bray–
Curtis distances, also showed no signi#cant di$erences between the control versus CHF groups (ANOSIM; 
R = 0.014, p = 0.335). However, a visual assessment of the principle coordinate analysis plot and Levene’s test sug-
gested a trend towards having a greater variation in the results of beta diversity in dogs with CHF (Levene’s test 
F(1,48) = 3.020, p = 0.089). Additional analyses of the subgroups of CHF and CHF dogs living with or without 
other CHF or healthy dogs also showed no di$erence in alpha and beta diversity between the groups (see Sup-
plementary Fig. S1 online).
Ǥ Taxa analysis showed 5 main Phyla: Firmicutes, Fusobacteria, Bacteroidetes, Proteobacteria, 
and Actinobacteria. !ere was a higher abundance of Proteobacteria in CHF dogs compared to the control dogs 
(p = 0.014; Table 3; Fig. 2). Linear discriminant analysis to the species level showed an increase in the abundance 
of Escherichia coli (p = 0.031) and an unclassi#ed species of Enterobacteriaceae (p = 0.002) within the Proteobac-
Table 2.  !e alpha diversity results from the 16S rRNA sequencing. !e results are displayed as mean (± s.d.) 
as they were normally distributed. CHF congestive heart failure, OTU operational taxonomic units, Faith’s PD 
Faith’s phylogenetic diversity.
Alpha diversity Control (n = 15) CHF (n = 35) p value
OTU 97.7 (± 18.0) 97.2 (± 22.7) 0.946
Shannon index 4.3 (± 0.6) 4.2 (± 0.6) 0.575
Faith’s PD 10.7 (± 1.8) 11.1 (± 2.0) 0.481
Figure 1.  Comparison of alpha (A) and beta diversity (B) between the control and congestive heart failure 
(CHF) groups. !e line in the alpha rarefaction curves (A) marks the mean and the error bars mark the 
standard deviation. !e principle coordinate analysis plot shows the results of Bray–Curtis dissimilarity analysis 
(B). !ere was no statistical signi#cance between the two groups in both analyses.
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teria of the CHF group. Other species with a relative increase in abundance in the CHF group were an unclassi-
#ed species of Roseburia (p = 0.024), an unclassi#ed species of Enterococcaceae (p = 0.013), Parabacteroides dista-
sonis (p = 0.049), an unclassi#ed species of Parabacteroides (p = 0.025), and Bacteroides uniformis (p = 0.031). In 
contrast, healthy dogs had an increased abundance of 5 bacterial species, which were: an unclassi#ed species of 
[Prevotella] (p = 0.033), an unclassi#ed species of Catenibacterium (p = 0.027), Clostridium cocleatum (p = 0.049), 
an unclassi#ed species of Erysipelotrichaceae (p = 0.001) and [Eubacterium] biforme (p = 0.006). Further results 
are displayed in Figs. 3, 4, and Supplementary Table S2 online.
Although there was a statistical di$erence at the Phyla level between the control and CHF groups, compar-
ing the subgroups of CHF did not show a statistical signi#cance (Proteobacteria Kruskal–Wallis p = 0.104; see 
Supplementary Table S3 online). !is suggested that the sample size for comparing multiple subgroups of CHF 
was underpowered. !erefore, further taxa analysis for subgroups of CHF was not performed.
Results of linear models showed that only 9 species were signi#cantly associated with clinicopathologic data. 
For each of these 9 species, only one variable remained signi#cant following multivariable analysis. !ese were: 
the presence of CHF for the unclassi#ed species of Enterococcaceae (p = 0.019), E. coli (p = 0.023), [Eubacterium] 
biforme (p = 0.035), and the unclassi#ed species of Erysipelotrichaceae (p = 0.040); total daily diuretic dose for the 
unclassi#ed species of Enterobacteriaceae (p = 0.002); MCS for the unclassi#ed species of Roseburia (p = 0.017), 
and the unclassi#ed species of Parabacteroides (p = 0.025); giving human food for the unclassi#ed species of 
Catenibacterium (p = 0.029); and #nally, living with another dog (in this case, a control dog) for the unclassi#ed 
species of [Prevotella] (p = 0.031).
Discussion
In this pilot study we compared the gut microbiome in dogs with CHF to healthy control dogs that were similar 
in age, sex, size and diet. Our results showed that quanti#able dysbiosis occurs in dogs with CHF, with the most 
pronounced #nding being an increase in the abundance of Proteobacteria, particularly due to an increase in E. 
coli and an unclassi#ed species of Enterobacteriaceae. While our pilot study design and the small sample size pre-
cluded us from detecting less pronounced e$ects of CHF on the gut microbiota and from performing subgroup 
analysis with an adequate statistical power, visual and statistical assessment of our data still suggested a greater 
variation in beta diversity, and a decrease in the abundance of Firmicutes species with butyrate producing poten-
tial, which is the more consistent dysbiosis pattern described in people with heart  failure21–25. A larger sample size 
Table 3.  Taxa analysis at Phylum level. !e median percentage abundance [25th, 75th percetiles] is displayed 
for the control and congestive heart failure (CHF) groups. Statistical signi#cance (p < 0.05) is marked bold.
Phylum Control (n = 15) CHF (n = 35)
p 
value
Firmicutes (%) 46.8 [36.7–57.0] 47.3 [31.3–62.4] 0.907
Fusobacteria (%) 25.8 [19.6–36.6] 20.6 [9.9–33.4] 0.153
Bacteroides (%) 17.7 [10.1–25.2] 17.7 [6.7–27.6] 0.975
Proteobacteria (%) 2.6 [1.0–4.9] 6.6 [2.4–11.7] 0.014
Actinobacteria (%) 0.6 [0.2–1.7] 0.8 [0.2–1.6] 0.759
Figure 2.  Stacked bar graphs showing the median percentage abundance of gut microbiota at the Phylum level.
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is needed to con#rm our #ndings in dogs, but our #ndings provide valuable preliminary information and support 
the concept that dogs may represent a clinically relevant animal model for dysbiosis in people with heart failure.
A recent canine study suggested that gut health is impaired in CHF by demonstrating greater concentrations 
of trimethylamine N-oxide (TMAO) in dogs with  CHF26–28. In a normal gut, certain gut microbes use dietary 
nutrients to produce trimethylamine, which is the precursor of TMAO. Bacteria capable of trimethylamine 
production include Gammaproteobacteria (E. coli, Citrobacter spp., Klebsiella pneumoniae, Providencia spp., and 
Shigella), Betaproteobacteria (Achromobacter spp.), Firmicutes (Sporosarcina spp.), and  Actinobacteria27,28. Act-
inobacteria and E. coli, were detected in our study, with the latter only found in the dogs with CHF. !e increased 
TMAO concentrations in  CHF26, could therefore have been associated with an increased abundance of E. coli.
Figure 3.  Results of linear discriminant analysis e$ect size (LEfSe). !e cladogram (A) shows di$erentially 
abundant bacterial taxa from the phylum to the species level. !e LEfSe result at the species level is further 
displayed in a plot (B). Only LEfSe scores > 2 are shown.
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An increase in the number of E. coli in dogs with CHF in this study is also consistent with a previous culturo-
mic study in human patients with heart  disease4 and may correspond with a vulnerable state of the gastrointesti-
nal tract common to both  species29. Similarly, the abundance of Enterococcaceae was increased in dogs with CHF. 
Metabolic studies have shown that certain genera of Enterococcaceae, E. coli and other related species may be more 
competitive in conditions of oxidative stress due to their ability to compensate with glutathione  production30. 
!is suggests that these bacteria are opportunistic and while some strains of E. coli are benign, some contain 
features that are compatible with  pathobionts30. Enterococcaceae and pathological strains of E. coli could induce 
in"ammation, which may contribute to the inappetence, malnutrition and cachexia seen in dogs with  CHF29,31.
In this study we have chosen 2 weeks to de#ne chronic CHF. !at said, CHF in dogs is generally considered 
a clinical manifestation of a chronic underlying heart condition since dogs tend to hide their symptoms and 
mild CHF is o%en missed by owners until it progresses to a point when the dog displays obvious signs such as 
tachpnoea and marked exercise intolerance. Although we have de#ned chronic CHF as 2 weeks, it is very likely 
Figure 4.  Box plots showing the results of 16S rRNA sequencing of di$erentially abundant bacterial species. 
!e box shows the respective 25th and 75th percentiles, the line within the box represented median value, 
and the whiskers show the lowest and highest data points still within 1.5 times the interquartile range of the 
respective lower and upper quartiles.
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that these dogs had mild but unobserved signs of CHF for a signi#cantly longer time period, more aligned with 
the clinical entity of chronic heart failure in human medicine.
One of the confounding variables assessed in this study was the e$ect of living with another dog. !e presence 
of a dog in the house in"uences the gut microbiota composition in  people32 and a similar e$ect was seen in dogs 
themselves, as they groom each other and sometimes exhibit  coprophagy33. !ese behaviours could introduce 
di$erent bacterial species that would otherwise not be present, leading to changes in the gut microbiota. When 
the CHF group was subclassi#ed, a trend in increasing alpha- and beta diversity was seen in those living with 
a healthy control dog, although this was not statistically signi#cant, probably due to the small sample size (see 
Supplementary Fig. S1 online). In our multivariable analysis, the greater abundance of the unclassi#ed species of 
[Prevotella] in the healthy dogs was independently associated with living with CHF dogs. Alteration in [Prevo-
tella] spp. has previously been observed in rhesus monkeys that underwent a change in social  structure34. !is, 
or a chance e$ect from a small sample size, may explain the contradictory #nding regarding the [Prevotella] 
abundance between our pilot study and the largest study in people on heart failure and the gut microbiome where 
the [Prevotella] abundance was increased with heart  failure23.
A proportion of dogs will lose their appetite with the development of CHF and when this occurs, the own-
ers are o%en advised to feed di$erent types of food in an attempt to meet the daily caloric requirement and 
minimise the e$ects of cardiac cachexia. Many owners share some of their meal with their dogs, and in line 
with veterinary advice, the shared foods are mostly protein based with no added salt (i.e., a portion of cooked 
chicken). !is feeding behaviour has previously been described in a questionnaire-based study in client owned 
dogs with  CHF35. In our study, only two dogs with CHF were found to be primarily eating human foods, while 
the remaining dogs with CHF were still eating commercial dog food as their primary diet, with occasional sup-
plementation using human food. We have accounted for some of this variation in diet by also keeping the diet 
heterogenous in the control group and by performing a multivariable analysis with the human food as one of the 
explanatory variables. Whilst this does not completely remove the subtle variation of nutrition in the dogs with 
CHF, only one bacterial species was found to be in"uenced by dogs eating human food. !is was the unclassi#ed 
species of Catenibacterium (family Erysipelotrichaceae), which was decreased in abundance in dogs with CHF. 
!e clinical signi#cance of the loss of Erysipelotrichaceae with CHF is unknown, although a depletion of core 
microbiota such as this, is a feature of dysbiosis in many diseases including heart failure, in"ammatory bowel 
disease and  diabetes13,22,31,36.
Our study has a number of limitations, mostly as a result of the inherent nature of a pilot study. As a result 
of the sample size we were only able to detect the most pronounced e$ect of CHF on the composition of the gut 
microbiome. Despite this, our data did suggest that the pattern of dysbiosis we observed appears to have similari-
ties to that observed in people with heart failure. Comparing multiple subgroups of CHF was not possible due 
to the lack of statistical power, and the results of the alpha- and beta diversity and taxa analyses therefore been 
shared as supplementary #les. Similarly, we have found that some of the bacterial species that were signi#cantly 
associated with the presence or absence of CHF in the linear discriminant analysis and Mann–Whitney U test, 
were not signi#cantly associated with any of the clinicopathological variables assessed, including the presence or 
absence of CHF, in a linear model. !ese were Clostridium cocleatum, Parabacteroides distasonis, and Bacteroides 
uniformis. However, the results for both the linear model and taxa analysis of multiple subgroups of CHF suggest 
that a larger sample size is required to rule out type II error. Another limitation in this study is the assumption of 
good health in the control dogs. !e dogs were deemed healthy on the basis of the history and a careful general 
and cardiac physical examination. Echocardiography was performed when there was a low-grade heart murmur 
or breed predisposition, to rule out an underlying cardiac disease. However, health screening blood tests were not 
performed in any dogs in the control group and whether some of the dogs had an early or pre-clinical systemic 
disease, such as chronic kidney disease, is unknown.
Overall, we have found that dogs with CHF have quanti#able dysbiosis with an increase in abundance of 
Proteobacteria (Enterobacteriaceae and E. coli). !e results of this pilot study provide useful preliminary infor-
mation and raise the possibility that dogs may represent a useful animal model of dysbiosis in people with heart 
failure, opening up the possibility of translatable clinical trials.
Materials and methods
Study design.  !is was a prospective, case-controlled pilot study, conducted at the Queen Mother Hospital 
for Animals (North Mymms, Royal Veterinary College) and a research clinic held at a #rst opinion practice by a 
diploma holding veterinary cardiologist (Camden, Royal Veterinary College). Ethics approval was provided by 
the Royal Veterinary College (M20160107).
Ǥ Client owned dogs with either LCHF, RCHF or BiCHF of at least 2 weeks duration were recruited. 
!e 2 weeks of duration was chosen for ‘chronic’ CHF. All dogs in the CHF group underwent echocardiogra-
phy by board certi#ed or eligible veterinary cardiologists. Le% congestive heart failure was de#ned as the pres-
ence of le% heart disease with le% atrial enlargement, pulmonary oedema detected on thoracic ultrasound or 
radiographs, and tachypnoea that resolved with furosemide. Right congestive heart failure was de#ned as the 
presence of right heart disease, right atrial enlargement and ascites that resolved or improved with furosemide. 
Lastly, BiCHF was de#ned when both criteria of LCHF and RCHF were met. Exclusion criteria were the use of 
an antibiotic or probiotic within 6 months prior to the sample collection, and any suspicion of an underlying 
enteropathy on the basis of history and review of available blood results.
Healthy dogs were enrolled into the control group while keeping the age and sex similar between the groups. 
Health was determined based on history and physical examination. Echocardiography was performed for breeds 
that were susceptible to dilated cardiomyopathy phenotype to rule out observable cardiac disease. When available, 
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a healthy dog cohabiting with a dog in the CHF group was recruited as a control dog. !e remaining dogs were 
owned by the hospital sta$ where the study was performed.
Data  collection.  Data collection included the signalment, diet, oral supplements, medications, appetite 
perceived by the owner (normal or reduced), number of dogs cohabiting with another dog, body weight,  BCS37 
and  MCS37. Cohabiting dogs were de#ned as those spending at least 80% of the day, for at least 6 months with 
the enrolled dog prior to the time of data  collection38. When dogs were receiving torsemide, the equivalent dose 
of furosemide was calculated by multiplying the torsemide dose by 20 for the purposes of statistical  analysis39.
	 Ǥ Samples collected following spontaneous defecation or by rec-
tal extraction were promptly stored at − 80 °C until the faecal DNA was extracted as a batch, using the QIA-
GEN DNeasy PowerSoil Kit (previously known as MoBio PowerSoil DNA Isolation Kit, QIAGEN), which has 
been validated for this  work40. !e eluted DNA sample was then shipped to an external laboratory (Molecular 
Research LP, Mr DNA, Shallowater, TX, https ://www.mrdna lab.com) for 16S rRNA sequencing (Illumina MiSeq 
platform) as previously  described41. !e QIIME 2  pipeline10 was used to analyse the faecal microbial communi-
ties, measuring the species present and their richness and diversity (α and β diversity), in the apparently healthy 
and a$ected dogs.
Statistical analysis.  R (Version 3.6.2, R Foundation for Statistical Computing, Vienna, Austria), SPSS (Ver-
sion 26.0.0.0, IBM Company, Chicago, IL), and Galaxy Hutlab server (https ://hutte nhowe r.sph.harva rd.edu/
galax y) were used for statistical analysis. GraphPad Prism 7 (GraphPad So%ware, San Diego, Ca) was used for 
production of graphs. Normality was assessed using Shapiro–Wilk tests and histograms. Normally distributed 
data were summarised as mean (± s.d.) and non-normally distributed data were summarised as median [25th, 
75th percentiles]. Depending on the distribution of data, continuous variables were compared using a student t 
test or Mann–Whitney test for 2 groups, and a one-way ANOVA or Kruskal–Wallis test for > 2 groups. Post-hoc 
analysis was performed using Tukey’s HSD test. Categorical variables were compared using Chi-squared tests. 
Alpha diversity was assessed by comparing operational taxonomic units, Faith’s phylogenetic diversity and Shan-
non Index between the groups using a student t test or Mann–Whitney test. Analysis of similarities (ANOSIM) 
and principal coordinate analysis were performed to assess the di$erence in beta diversity. For comparison of 
both alpha- and beta-diversity, homogeneity of variance was also assessed using Levene’s test. Bacterial taxa that 
were identi#ed in < 10% of the faecal samples were removed from the taxa analysis. Linear discriminant analysis 
(LDA) e$ect size was used to detect di$erentially abundant taxa at the species level, between the control and 
CHF groups. Among those bacterial species with di$erential abundance, the e$ects of age, consuming human 
food, living with another dog, MCS, total daily diuretic dose, presence of CHF, subclassi#cation of CHF, and 
duration of CHF, on the log transformed read counts, were further explored using a general linear model in a 
backward stepwise manner. Signi#cance was set at p < 0.05.
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